BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34369368)

  • 1. Malignancies in spondyloarthritis with and without concomitant psoriasis, and the effect of disease modifying anti-rheumatic drugs.
    Chung HY; Chan SCW; Chui ETF; Yau T; Lau CS
    Clin Exp Rheumatol; 2022 May; 40(5):913-920. PubMed ID: 34369368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of nonpulmonary infections requiring hospitalization in spondyloarthritis.
    Chung HY; Chan SCW; Sun FSK
    Immun Inflamm Dis; 2022 May; 10(5):e615. PubMed ID: 35478442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of community-acquired pneumonia requiring hospitalization in patients with spondyloarthritis.
    Chung HY; Tam LS; Chan SCW; Cheung JPY; Wong PY; Ciang CO; Ng HY; Law MY; Lai TL; Wong CH;
    Ther Adv Musculoskelet Dis; 2020; 12():1759720X20962618. PubMed ID: 33133244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional and Biologic Disease-Modifying Antirheumatic Drugs Are Not Associated With Increase in or Progression of Cervical Neoplasia Among Patients With Spondyloarthritis.
    Li PH; Chan SCW; Lau CS; Seto MTY; Chung HY
    J Clin Rheumatol; 2022 Jan; 28(1):e63-e68. PubMed ID: 33105316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of cutaneous herpes zoster in patients with spondyloarthritis treated with conventional and biologic disease-modifying antirheumatic drugs.
    Wong SCT; Li IWS; Ng AHY; Lau CS; Chung HY
    Int J Rheum Dis; 2020 Feb; 23(2):189-196. PubMed ID: 31489783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases.
    Fatica M; Monosi B; Conigliaro P; D'Antonio A; Essofi S; Cuccagna E; Bergamini A; Biancone L; Monteleone G; Triggianese P; Calabrese E; Chimenti MS
    RMD Open; 2024 Jan; 10(1):. PubMed ID: 38296800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of tuberculosis in patients with spondyloarthritis: data from a centralized electronic database in Hong Kong.
    Ciang NC; Chan SCW; Lau CS; Chiu ETF; Chung HY
    BMC Musculoskelet Disord; 2020 Dec; 21(1):832. PubMed ID: 33302934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs.
    Chan SCW; Teo CK; Li PH; Lau KK; Lau CS; Chung HY
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211032444. PubMed ID: 34377159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis.
    Chung TT; Ko HJ; Lau CS; Chung HY
    Rheumatol Int; 2020 Jun; 40(6):983-990. PubMed ID: 32318800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axial spondyloarthritis: thoughts about nomenclature and treatment targets.
    Braun J
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S132-5. PubMed ID: 23079005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying anti-rheumatic drugs for refractory severe knee synovitis in patients with peripheral spondyloarthritis: efficacy and predictors of response.
    Sakellariou GT; Sayegh FE; Anastasilakis AD; Bisbinas I; Kapetanos GA
    Scand J Rheumatol; 2013; 42(5):369-72. PubMed ID: 23607529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Backfill is a specific sign of axial spondyloarthritis seen on MRI.
    Hu Z; Wang X; Qi J; Kong Q; Zhao M; Gu J
    Joint Bone Spine; 2016 Mar; 83(2):179-83. PubMed ID: 26709251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study.
    Nikiphorou E; van der Heijde D; Norton S; Landewé RB; Molto A; Dougados M; Van den Bosch FE; Ramiro S
    Ann Rheum Dis; 2018 Mar; 77(3):405-411. PubMed ID: 29222349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
    Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical importance of the thyroid nodules during anti-tumor necrosis factor therapy in patients with axial spondyloarthritis.
    Terlemez R; Akgün K; Palamar D; Boz S; Sarı H
    Clin Rheumatol; 2017 May; 36(5):1071-1076. PubMed ID: 28357602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
    Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
    Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Targeted treatment in spondyloarthritis].
    Zanisi L; Nissen MJ
    Rev Med Suisse; 2020 Mar; 16(685):482-486. PubMed ID: 32167249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis: results of an international survey.
    van der Heijde D; Sieper J; Elewaut D; Deodhar A; Pangan AL; Dorr AP
    J Clin Rheumatol; 2014 Dec; 20(8):411-7. PubMed ID: 25417676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study.
    Sepriano A; Ramiro S; van der Heijde D; Ávila-Ribeiro P; Fonseca R; Borges J; Teixeira L; Carvalho PD; Cerqueira M; Neves J; Meirinhos T; Barcelos A; Sequeira G; Salvador MJ; Canas da Silva J; Santos H; Bernardes M; Vieira-Sousa E; Canhão H; Branco JC; Pimentel-Santos F; Landewé R
    Arthritis Rheumatol; 2016 Nov; 68(11):2671-2679. PubMed ID: 27273894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cross-sectional study on clinical characteristics of Saudi axial spondylarthritis: preliminary results.
    Bedaiwi MK; AlRasheed RF; Bin Zuair A; Alqurtas EM; Baeshen MO; Omair MA
    Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5241-5247. PubMed ID: 34486699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.